Parkinson’s Disease

The impact of our research

Parkinson’s disease is the second most common neurological disease in Australia after dementia. There is currently no cure. Our medical research teams are focused on better understanding its underlying causes and improving treatments.

QIMR Berghofer researchers have made a breakthrough in understanding how to make one of the most widely used treatments for Parkinson’s disease safer and more effective.

We’re running the Australian Parkinson’s Genetics Study (APGS), a groundbreaking research program that aims to identify genetic factors that increase the risk of developing Parkinson’s disease.

About Parkinson’s disease

What is Parkinson’s disease?

Parkinson’s disease (PD) affects brain cells that produce dopamine in a specific area of the brain. Dopamine is a chemical messenger that plays an important role in pleasure, motivation, and learning. A dopamine imbalance is linked to mental illness, addiction, and Parkinson’s disease.

What causes Parkinson’s disease?

The causes of Parkinson’s disease are complex. Nearly 15% of people with PD have a family history of the disease, while up to 5% have a form of the disease that’s influenced by just one gene.

The remaining cases – almost 80% – are thought to result from a combination of genetic and environmental factors, but the exact cause is unknown.

With our ageing population and longer life expectancy, diagnoses of PD are expected to increase dramatically over the coming decades.

Who’s most at risk of Parkinson’s disease?

The average age of diagnosis is 60. Anything younger than 50 is considered to be early-onset disease.

What are the symptoms of Parkinson’s disease?

There are significant differences between individuals in the onset, intensity and progression of Parkinson’s disease (PD). The disease is typically defined by its motor features, such as:

  • the body becoming rigid;
  • slowness of movement;
  • disturbed gait;
  • tremor.

However, PD patients also experience several non-motor symptoms, including:

  • REM sleep behaviour disorder
  • constipation
  • urinary incontinence
  • light-headedness or dizziness
  • depression
  • apathy
  • decreased sense of smell
  • cognitive impairment.

PD patients are six times more likely to develop dementia than the general population.

Parkinson’s disease in Australia

Parkinson’s disease is the second most common neurological disease in Australia after dementia. More than 150,000 Australians are living with Parkinson’s disease, and 50 more are diagnosed every day.

How is Parkinson’s disease treated?

There is currently no cure. Treatment options focus on managing symptoms. In some cases surgery may be advised. Lifestyle changes, especially aerobic exercise, physical therapy for balance and stretching, and speech pathology are recommended.

Facts about parkinson’s disease

2nd
most common neurodegenerative disorder worldwide.
2–3%
of Australians aged 65+ affected.
120,000+
people affected by Parkinson’s in Australia, with a new patient diagnosed every 45 minutes.

Our Parkinson’s disease research

Clinical trials & research studies